KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Xenon Pharmaceuticals (XENE) Net Cash Flow: 2012-2024

Historic Net Cash Flow for Xenon Pharmaceuticals (XENE) over the last 13 years, with Dec 2024 value amounting to -$4.3 million.

  • Xenon Pharmaceuticals' Net Cash Flow rose 37.23% to -$30.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $17.5 million, marking a year-over-year increase of 249.67%. This contributed to the annual value of -$4.3 million for FY2024, which is 104.68% down from last year.
  • Per Xenon Pharmaceuticals' latest filing, its Net Cash Flow stood at -$4.3 million for FY2024, which was down 104.68% from $91.0 million recorded in FY2023.
  • Xenon Pharmaceuticals' Net Cash Flow's 5-year high stood at $131.3 million during FY2021, with a 5-year trough of -$116.0 million in FY2022.
  • Over the past 3 years, Xenon Pharmaceuticals' median Net Cash Flow value was -$4.3 million (recorded in 2024), while the average stood at -$9.7 million.
  • Per our database at Business Quant, Xenon Pharmaceuticals' Net Cash Flow surged by 529.69% in 2021 and then tumbled by 188.34% in 2022.
  • Yearly analysis of 5 years shows Xenon Pharmaceuticals' Net Cash Flow stood at $20.8 million in 2020, then skyrocketed by 529.69% to $131.3 million in 2021, then plummeted by 188.34% to -$116.0 million in 2022, then surged by 178.50% to $91.0 million in 2023, then plummeted by 104.68% to -$4.3 million in 2024.